# Durability of Icotrokinra (Targeted Oral Peptide) Effects in Adolescents With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the ICONIC-LEAD Study

Jennifer Soung,[1] Mark G. Lebwohl,[2] Adelaide Hebert,[3] Andrew E. Pink,[4] Yuling Shi,[5] Megan Miller-Kassamali,[6] Joseph Cafone,[6] Jingzhi Jiang,[6] Shu Li,[6] Ya-Wen Yang,[7] Lawrence F. Eichenfield[8]

[1]Southern California Clinical Research, Santa Ana, and Harbor University of California Los Angeles, CA, USA; [2]Icahn School of Medicine at Mount Sinai, New York, NY, USA; [3]UTHealth McGovern Medical School, Houston, TX, USA; [4]St. John's Institute of Dermatology, Guy's & St. Thomas' NHS Foundation Trust and King's College London, London, UK; [5]Shanghai Skin Disease Hospital and Institute of Psoriasis at the Tongji University School of Medicine, Shanghai, China; [6]Johnson & Johnson, Spring House, PA, USA; [7]Johnson & Johnson, Horsham, PA, USA; [8]University of California, San Diego School of Medicine, and Rady Children's Hospital, San Diego, CA, USA



This presentation was sponsored by Johnson & Johnson.

Presented at: AAD Annual Meeting; March 27-31, 2026; Denver, Colorado, USA.

# Disclosures

**JS:** Served as a speaker, consultant, advisory board member and/or investigator for AbbVie, Amgen, Arcutis, Aslan, Bristol Myers Squibb, Coval Biopharma, Dermavant, Eli Lilly, Johnson & Johnson, KoBio Labs, National Psoriasis Foundation, Novartis, Ortho Dermatologic, Oruka, Pfizer, Regeneron/Sanofi, and UCB.

**MGL:** Employee of Mount Sinai; receives research funds from AbbVie, Arcutis, Avotres, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Clexio, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Johnson & Johnson, Oruka, Pfizer, Sanofi-Regeneron, and UCB; and is a consultant for AbbVie, Added Health, Aikium, Almirall, AltruBio Inc., Alumis, Amgen, Apogee, Arcutis, AstraZeneca, Atomwise, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, Celltrion, CorEvitas, Dermavant Sciences, Dermsquared, Edesa Biotech, Eli Lilly, Evommune, Facilitation of International Dermatology Education, Forte Biosciences, Galderma, Genentech, Johnson & Johnson, Incyte, LEO Pharma, Mayne Pharmaceuticals, Meiji Seika Pharma, Mindera, Mirium Pharmaceuticals, Moonlake, Oruka, Pfizer, Sanofi-Regeneron, Revolo, Seanergy, Strata, Sun Pharma, Takeda, Trevi, and Verrica.

**AH:** Employee of UTHealth McGovern Medical School-Houston; research grants paid to medical school by AbbVie, Arcutis, Dermavant, Eli Lilly, Johnson & Johnson, Pfizer, and Takeda; received honoraria from Almirall, Apogee, Arcutis, Castle Biosciences, Dermavant, Incyte, Johnson & Johnson, Pfizer, and Verrica; served on DSMB: GlaxoSmithKline, OrthoDermatologics, and Sanofi-Regeneron.

**AEP:** Served as an investigator, advisor and/or speaker and/or received educational support from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galderma, Incyte, Johnson & Johnson, LEO Pharma, Novartis, Pfizer, Sanofi, and UCB.

**YS:** Reported no disclosures.

**MM-K, JC, JJ, SL,** and **Y-WY:** Employees of Johnson & Johnson; may own stock/stock options in Johnson & Johnson.

**LFE:** Served as an investigator, advisor, and/or speaker for AbbVie, Abeona, Acrotech, Almirall, Amgen, Apogee, Arcutis, Attovia, Bristol Myers Squibb, Castle Biosciences, Chiesi, CorEvitas, Dermavant, Eli Lilly, Formation Bio, Forte, Galderma, Incyte, Johnson & Johnson, Kenvue, Kymera, Krystal, LEO Pharma, Novartis, OrthoDerm, Pfizer, Regeneron, Sanofi Genzyme, Takeda, Target RWE, T-Rex, UCB, and Verrica.

# Background

## Pediatric plaque psoriasis

Approximately one-third of patients with plaque psoriasis (PsO) report onset before adulthood; however, few advanced treatment options are available[1]

## Icotrokinra

Patients with moderate-to-severe plaque PsO are limited to injectable therapies to achieve high-level efficacy with a favorable safety profile

Icotrokinra (ICO), the first and only targeted oral peptide:

- Precisely blocks the interleukin (IL)-23 receptor and inhibits IL-23 pathway signaling[2]
- Demonstrated significantly higher rates of skin clearance vs placebo (PBO) at Week (W)16, with increasing response rates and no safety signal through W24 among all adult and adolescent participants (pts) with moderate-to-severe plaque PsO in the phase 3 ICONIC-LEAD study[3]
  - ICO showed higher skin clearance rates vs PBO at W16 in the adolescent subgroup, with increased response rates and a favorable safety profile through W24[4]




**IFN**=interferon, **IL-12Rβ1**=interleukin-12 receptor beta 1, **IL-23Ri**=interleukin-23 receptor inhibitor.

# Objective

**Assess longer-term ICO effects and safety in ICONIC-LEAD adolescents through W52**

# ICONIC-LEAD – Study Design & Adolescent Subgroup

## Moderate-to-Severe Plaque PsO (N=684)

***Key inclusion criteria***

- ≥12 years
  - Adults (≥18 years)
  - Adolescents (12-<18 years)
- Plaque PsO for ≥26 weeks
- BSA ≥10%, PASI score ≥12, IGA score ≥3
- Candidate for phototherapy or systemic treatment for plaque PsO

***Adolescent-specific inclusion criteria:***

- Body weight ≥40 kg[a]




[a]Weight limit was set to ensure similar exposures between adults and adolescents. [b]Pts retreated with ICO upon loss of ≥50% PASI improvement observed at W24. **BSA**=body surface area, **IGA**=Investigator's Global Assessment, **PASI**=Psoriasis Area and Severity Index, **QD**=once daily, **R**=randomization.

# Outcomes & Analyses

| | |
|---|---|
| **Through W52** | • IGA 0/1 & ≥2-grade improvement from baseline (IGA 0/1), PASI 90<br>• IGA 0, PASI 100<br>• AEs: Number (%) of adolescents and exposure-adjusted incidence rates (per 100 PY) |
| **At W52** | • IGA 0/1 among W24 IGA 0/1 responders<br>• PASI 90 among W24 PASI 90 responders |
| **Analyses** | • Nonresponder imputation: Pts who discontinued study drug due to a lack of efficacy or an AE of worsening PsO, or initiated prohibited medication that could impact PsO<br>• Observed data: Pts who discontinued study drug for other reasons<br>• After accounting for the intercurrent events, pts with missing data were considered nonresponders |



**AE**=adverse event, **PY**=participant-years.

# Adolescent characteristics were generally balanced between groups

| Baseline Characteristics in Adolescents | | ICO (N=44) | PBO (N=22) |
|---|---|---|---|
| **Demographics** | | | |
| | **Age,** yrs | 15.0 (1.8) | 15.0 (1.5) |
| | **Female** | 52% | 64% |
| | **Race,** Asian / Black / White | 23% / 5% / 70% | 23% / 0% / 77% |
| | **BMI,** kg/m$^2$ | 26.0 (7.1) | 24.4 (7.9) |
| **Disease Characteristics** | | | |
| | **PsO disease duration**, yrs | 4.9 (4.0) | 5.8 (3.4) |
| | **% of BSA with PsO** | 26.1 (15.6) | 27.1 (14.0) |
| | **IGA score** | | |
| | Moderate (3) | 70% | 82% |
| | Severe (4) | 30% | 18% |
| | **PASI** (0-72) | 19.8 (8.2) | 18.6 (4.0) |
| **Prior PsO Treatments** | | | |
| | **Phototherapy (PUVA or UVB)** | 23% | 14% |
| | **Systemic therapy**[a] | 52% | 50% |
| | Biologic therapy[b] | 14% | 41% |



Data shown are mean (SD), unless otherwise noted. [a]Conventional nonbiologic systemics, novel nonbiologic systemics, 1,25-vitamin D3 and analogues, phototherapy, and biologics. [b]Adalimumab, alefacept, briakinumab, brodalumab, certolizumab pegol, efalizumab, etanercept, guselkumab, infliximab, ixekizumab, natalizumab, risankizumab, secukinumab, tildrakizumab, and ustekinumab.
**BMI**=body mass index, **PUVA**=psoralen plus ultraviolet A, **SD**=standard deviation, **UVB**=ultraviolet B.

# ICO demonstrated high rates of IGA 0/1 & PASI 90 by W24, with >80% of pts exhibiting clear/almost clear skin during W24-52

- After transitioning to ICO, PBO-randomized pts achieved IGA 0/1 and PASI 90 response rates at W52 that were consistent with those achieved by ICO-randomized pts




**Nominal *$p<0.05$, **$p<0.01$, ***$p<0.001$ vs PBO**



P-values based on Cochran-Mantel-Haenszel chi-square test stratified by geographic region. Known differences between IGA vs PASI score determinations likely account for differences in response rates. **CI**=confidence interval, **IGA 0/1**=IGA score 0/1 & ≥2-grade improvement from baseline.

# ~90% of ICO-randomized adolescents achieving clear/almost clear skin at W24 maintained response at W52






Known differences between IGA vs PASI score determinations likely account for differences in response rates. **IGA 0/1**=IGA score 0/1 & ≥2-grade improvement from baseline.

# ICO demonstrated high rates of IGA 0 & PASI 100 by W24, with ~60% of pts exhibiting complete skin clearance during W24-52

- After transitioning to ICO, PBO-randomized pts achieved IGA 0 and PASI 100 response rates at W52 that were consistent with those achieved by ICO-randomized pts




**Nominal *$p$<0.05, **$p$<0.01, ***$p$<0.001 vs PBO**



P-values based on Cochran-Mantel-Haenszel chi-square test stratified by geographic region. Known differences between IGA vs PASI score determinations likely account for differences in response rates.

# The ICO AE profile in adolescents was similar to PBO through W16, and consistent between W16 & W52

| AEs Through W52: Adolescents[a] | PBO-Controlled (Through W16) | | Through W52 |
|---|---|---|---|
| | PBO (N=22) | ICO (N=44) | ICO Combined (N=66)[a] |
| **Mean weeks / total PY of follow-up** | 16.2 / 6.8 | 16.2 / 13.7 | 46.3 / 58.6 |
| **Any AE** | 16 (73%) | 22 (50%) | 46 (70%) |
| **Incidence/100 PY (95% CI)[b,c]** | 521 (266, 776) | 238 (139, 338) | 164 (117, 212) |
| **Serious AE** | 0 | 2 (5%) | 4 (6%) |
| **Incidence/100 PY (95% CI)[b,d]** | 0 (0, 44) | 15 (2, 54) | 7 (2, 18) |
| **AE leading to discontinuation** | 0 | 0 | 0 |
| **Incidence/100 PY (95% CI)[b,d]** | 0 (0, 44) | 0 (0, 22) | 0 (0, 5) |
| **Infection** | 6 (27%) | 14 (32%) | 31 (47%) |
| **Incidence/100 PY (95% CI)[b,c]** | 116 (23, 209) | 130 (62, 198) | 78 (50, 105) |
| **Serious infection** | 0 | 0 | 0 |
| **Incidence/100 PY (95% CI)[b,d]** | 0 (0, 44) | 0 (0, 22) | 0 (0, 5) |
| **Gastrointestinal AE** | 1 (5%) | 2 (5%) | 5 (8%) |
| **Incidence/100 PY (95% CI)[b,d]** | 15 (<1, 85) | 15 (2, 53) | 9 (3, 21) |
| **Malignancy** | 0 | 0 | 0 |
| **Incidence/100 PY (95% CI)[b,d]** | 0 (0, 44) | 0 (0, 22) | 0 (0, 5) |



Data shown are n (%), unless otherwise noted. Safety analysis set included all randomized and treated pts. [a]Includes pts receiving ICO through W52 and data after W16 for pts receiving PBO who transitioned to ICO. [b]Incidence/100 PY: (number of pts with AEs/total PY at risk) × 100. [c]CIs were based on a Wald statistic using the normal assumption. [d]CIs were based on an exact method assuming that the observed number of events follows a Poisson distribution.

# Key Takeaways

**In ICONIC-LEAD, adolescents with moderate-to-severe plaque PsO receiving ICO:**

- ✓ **Achieved high rates of skin clearance by W24, with >80% demonstrating clear/almost clear skin & ~60% exhibiting complete skin clearance during W24-52**
  - ✓ **~90% of ICO adolescents achieving IGA 0/1 or PASI 90 at W24 maintained response at W52**
- ✓ **ICO demonstrated a favorable safety profile in adolescents through W52 that was consistent with the overall study population[5]; no ICO safety signal was identified**

**Findings further support the use of ICO, a targeted oral peptide, to treat moderate-to-severe plaque PsO in adolescents, addressing an important unmet need with a once-daily pill**

*For patient-reported outcomes of the ICONIC-LEAD adolescent cohort through W52, please visit our companion AAD poster (ID: 73603)*

# References


1. Diotallevi F. *Int J Mol Sci*. 2022;23:11128.
2. Fourie AM. *Sci Rep*. 2024;14:17515.
3. Bissonnette R. *N Engl J Med*. 2025;393:1784-95.
4. Eichenfield L. World Congress of Pediatric Dermatology; April 8-11, 2025; Buenos Aires, Argentina.
5. Soung J. Presented at: EADV Congress; September 17, 2025; Paris, France.

# Acknowledgments


- Medical writing support was provided by R. Contento, PharmD of Johnson & Johnson under the direction of the authors in accordance with Good Publication Practice guidelines (*Ann Intern Med*. 2022;175:1298-1304).

- This presentation was sponsored by Johnson & Johnson.